Alembic Pharmaceuticals gets FDA final approval for Doxepin Hydrochloride Capsules

TAGS

Alembic Pharmaceuticals announces USFDA Final Approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg.

Alembic Pharmaceuticals has secured final approval from the US Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.

See also  Pfizer's immunotherapy ELREXFIO approved in EU for multiple myeloma

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) – Pfizer’s Sinequan Capsules 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.

Alembic Pharmaceuticals gets FDA final approval for Doxepin Hydrochloride Capsules

Alembic Pharmaceuticals gets FDA final approval for Doxepin Hydrochloride Capsules

Doxepin Hydrochloride Capsules are used for the treatment of psychoneurotic patients with depression and/or anxiety, depression and/or anxiety resulting from alcoholism, depression and/or anxiety related to organic disease, psychotic depressive disorders with associated anxiety.

See also  Lupin gets FDA nod for generic equivalent of Doryx delayed-release tablets

Alembic Pharmaceuticals has a total of 141 ANDA approvals, which include 124 final approvals and 17 tentative approvals from the FDA.

CATEGORIES
TAGS
Share This